Dapagliflozin
Dapagliflozin (BMS-512148) is a selective SGLT2 inhibitor used in type 2 diabetes research. By competitively blocking renal glucose reabsorption, it promotes glucosuria and lowers blood glucose. This mechanism is studied in vitro and in vivo for metabolic disease and cardiovascular research applications.
Product Specifications
CAS Number
461432-26-8
Product Name Alternative
Sodium-dependent glucose cotransporters, SGLT, hSGLT2, Inhibitor, HIF1, inhibit, Dapagliflozin, BMS512148, BMS-512148, BMS 512148
Field of Research
Cardiovascular Research, Epigenetics & Chromatin, Pharmacology & Drug Discovery
Purity
99.50% (May vary between batches)
Solubility
H2O:< 1 mg/mL (insoluble or slightly soluble) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:4.5 mg/mL (11.01 mM) ; Ethanol:14 mg/mL (34.24 mM) ; DMSO:247.5 mg/mL (605.33 mM)
Smiles
O[C@H]1[C@@H] (O[C@H] (CO) [C@@H] (O) [C@@H]1O) C2=CC (CC3=CC=C (OCC) C=C3) =C (Cl) C=C2
Molecular Formula
C21H25ClO6
Molecular Weight
408.87
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNUB1373-500 1x 500 µL
Ep-CAM / CD326 (Extracellular Domain) (Epithelial Marker) (EGP40/1373), 0.2mg/mL
Sign In for Pricing
View Details